Sign in Subscribe
Cancer

Gastric Cancer Peritoneal Metastasis Research Suggests Shift Towards Precision and Personalized Treatment

Strategic Insights

— 1 min read

Recent research on gastric cancer peritoneal metastasis (GCPM) has identified significant trends and hotspots in the field, highlighting the need for precision and personalized treatment. GCPM is a challenging and difficult-to-treat condition, with a low 5-year survival rate. The study analyzed 2416 publications on GCPM from 2004 to 2024, revealing a positive growth rate until 2021, with a slowdown expected in the near future.

Key Takeaways:

  • Japan dominated the research output on GCPM, with 842 publications, followed by China (748 publications) and the United States (268 publications).
  • Japanese-affiliated organizations and researchers are extremely productive in the field of GCPM, accounting for 35% of all publications.
  • The most frequently cited document was the Japanese gastric cancer treatment guidelines 2014 (ver. 4) with 2076 citations.
  • Research focuses on four major clusters: molecular mechanisms of GCPM, prognosis of GCPM, chemotherapy of GCPM, and intraperitoneal treatment of GCPM.
  • Emerging trends include key pathways of GCPM, artificial intelligence (AI) and multi-omics-driven early diagnosis, novel intraperitoneal therapeutic modalities, and immunologic/targeted drugs.
  • The study concludes that there is a need to promote global collaborative trials and optimization of multimodality therapy to address the lack of standardized validation systems for emerging technologies and regional differences in clinical practice.

Statistics:

  • 2416 publications on GCPM were analyzed from 2004 to 2024.
  • Japan produced 842 publications on GCPM, accounting for 35% of all publications.
  • China produced 748 publications on GCPM, accounting for 31% of all publications.
  • The United States produced 268 publications on GCPM, accounting for 11% of all publications.
  • The most frequently cited document was the Japanese gastric cancer treatment guidelines 2014 (ver. 4) with 2076 citations.
  • Research hotspots included molecular mechanisms of GCPM, prognosis of GCPM, chemotherapy of GCPM, and intraperitoneal treatment of GCPM.

Sources:

  • Two decades of progress in gastric cancer peritoneal metastasis: a bibliometric perspective on molecular mechanisms and therapeutic innovations. Frontiers in Oncology, 2025;15:1583364.
  • Zhejiang Hospital, Department of Oncology, Hangzhou, People's Republic of China.
  • Xiaoxuan Tu, Jin Qian, Jianglin Chen, Sisi Chen, Yi Zhou, Chuan Sun, and Zhibing Wu.

Read more